Background: Evaluation of treatment options for localized prostate cancer (PCa) remains among the highest priorities for comparative effectiveness research. Surgery and radiotherapy (RT) are the two interventions most commonly used. Objective: To provide a critical narrative review of evidence of the comparative effectiveness and harms of surgery and RT in the treatment of localized PCa. Evidence acquisition: A collaborative critical narrative review of the literature was conducted. Evidence synthesis: Evidence to clearly guide treatment choice in PCa remains insufficient. Randomized trials are underpowered for clinically meaningful endpoints and have demonstrated no difference in overall or PCa-specific survival. Observational studies have...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
BACKGROUND:The ProtecT trial reported intention-to-treat analysis of men with localised prostate can...
BACKGROUND:The ProtecT trial reported intention-to-treat analysis of men with localised prostate can...
Context: The optimal treatment for men with high-risk localized or locally advanced prostate cancer ...
Background: The ProtecT trial reported intention-to-treat analysis of men with localised prostate ca...
Context: The optimal treatment for men with high-risk localized or locally advanced prostate cancer ...
BACKGROUND:The ProtecT trial reported intention-to-treat analysis of men with localised prostate can...
Background The ProtecT trial reported intention-to-treat analysis of men with localised prostate ca...
Background Robust data on patient-reported outcome measures comparing treatments for clinically loca...
ImportanceUnderstanding the adverse effects of contemporary approaches to localized prostate cancer ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
BACKGROUND Robust data on patient-reported outcome measures comparing treatments for clinically loca...
Context The optimal treatment for men with high-risk localized or locally advanced prostate cancer ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
BACKGROUND:The ProtecT trial reported intention-to-treat analysis of men with localised prostate can...
BACKGROUND:The ProtecT trial reported intention-to-treat analysis of men with localised prostate can...
Context: The optimal treatment for men with high-risk localized or locally advanced prostate cancer ...
Background: The ProtecT trial reported intention-to-treat analysis of men with localised prostate ca...
Context: The optimal treatment for men with high-risk localized or locally advanced prostate cancer ...
BACKGROUND:The ProtecT trial reported intention-to-treat analysis of men with localised prostate can...
Background The ProtecT trial reported intention-to-treat analysis of men with localised prostate ca...
Background Robust data on patient-reported outcome measures comparing treatments for clinically loca...
ImportanceUnderstanding the adverse effects of contemporary approaches to localized prostate cancer ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
BACKGROUND Robust data on patient-reported outcome measures comparing treatments for clinically loca...
Context The optimal treatment for men with high-risk localized or locally advanced prostate cancer ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...